Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Monocular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Monocular. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-001436-22 Sponsor Protocol Number: APL2-303 Start Date*: 2018-12-07
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A...
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001435-52 Sponsor Protocol Number: APL2-304 Start Date*: 2018-12-10
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A...
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002931-32 Sponsor Protocol Number: APL2-GA-305 Start Date*: 2021-09-17
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001091-30 Sponsor Protocol Number: FG-PRE-101 Start Date*: 2016-10-17
    Sponsor Name:ORASIS Pharmaceuticals Ltd
    Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability, and Efficacy of PresbiDrops in Presbyopic Subjects
    Medical condition: Presbyopia is part of the natural ageing process of the eye. It is usually noticed at around the age of 40 years. The main symptom of this condition is a progressive blurring of vision when perform...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-001198-22 Sponsor Protocol Number: ALXN2040-GA-201 Start Date*: 2021-12-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001496-20 Sponsor Protocol Number: SMR3438 Start Date*: 2019-05-14
    Sponsor Name:Katairo GmbH
    Full Title: A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease
    Medical condition: Stargardt Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003029-40 Sponsor Protocol Number: IOBA-01-2016 Start Date*: 2017-02-14
    Sponsor Name:IOBA - University of Valladolid
    Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION)
    Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005400-14 Sponsor Protocol Number: WONR1001 Start Date*: 2008-07-25
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: PERIOPERATIVE INTRAVITREAL TRIAMCINOLONE IN PHAKOEMULSIFICATION FOR CONCURRENT CLINICALLY SIGNIFICANT DIABETIC MACULAR OEDEMA
    Medical condition: Diabetic Maculopathy: Clinically significant macular oedema To understand the effects of intravitreal triamcinolone (IVTA) in the treatment of clinically significant macular edema (CSME) in diabet...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003373-64 Sponsor Protocol Number: 01-DIMS-2021 Start Date*: 2021-11-22
    Sponsor Name:NOEMI GUEMES VILLAHOZ
    Full Title: POST-MARKETING PARALLEL CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS AND TOLERABILITY OF DIMS LENSES IN THE CONTROL OF MYOPIA IN PEDIATRIC POPULATION
    Medical condition: MYOPIA IN PEDIATRIC POPULATION
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000352-19 Sponsor Protocol Number: MOG001 Start Date*: 2022-01-17
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants ...
    Medical condition: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10012302 Demyelinating disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005173-95 Sponsor Protocol Number: DX219 Start Date*: 2022-09-01
    Sponsor Name:Oculis SA
    Full Title: A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005317-37 Sponsor Protocol Number: THR-2010-01 Start Date*: 2012-06-14
    Sponsor Name:Thrombotech Ltd.
    Full Title: Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPA
    Medical condition: Acute isquemic stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002546-36 Sponsor Protocol Number: 2018-002546-36 Start Date*: 2020-03-10
    Sponsor Name:Oslo University Hospital
    Full Title: TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA...
    Medical condition: Central retinal artery occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Completed) FI (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004982-28 Sponsor Protocol Number: FFIS/PG/2017/03 Start Date*: 2018-05-23
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Phase IIb prospective, unicentric, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the intravenous infusion of prostaglandins as therapy in patients with non-arter...
    Medical condition: Non-arteritic anterior ischemic optic neuropathy (NOIANA).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023001-36 Sponsor Protocol Number: BAY86-4875/14607 Start Date*: 2011-04-26
    Sponsor Name:Bayer Health Care AG
    Full Title: Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/k...
    Medical condition: Subjects with known or suspected vascular disease of the supra-aortic vessels
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) FR (Completed) IT (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002431-30 Sponsor Protocol Number: GT005-03 Start Date*: 2020-10-21
    Sponsor Name:Gyroscope Therapeutics
    Full Title: HORIZON: A Phase II, open-label, outcomes-assessor masked, multicentre, randomised,controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal inj...
    Medical condition: Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The prima...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022965-82 Sponsor Protocol Number: 201050 Start Date*: 2010-12-22
    Sponsor Name:Santen Oy
    Full Title: A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to ...
    Medical condition: Ocular hypertension and POAG, capsular glaucoma and pigmentary glaucoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10035015 Pigmentary glaucoma PT
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10036719 Primary open angle glaucoma LLT
    14.1 10015919 - Eye disorders 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) EE (Completed) NL (Completed) PL (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000183-29 Sponsor Protocol Number: REVISION Start Date*: 2022-03-09
    Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director
    Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co...
    Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007971 Central retinal artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022984-36 Sponsor Protocol Number: 201051 Start Date*: Information not available in EudraCT
    Sponsor Name:Santen Oy
    Full Title: A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to ...
    Medical condition: Patients diagnosed with ocular hypertension or open-angle glaucoma (primary open-angle glaucoma [POAG], capsular glaucoma or pigmentary glaucoma).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030043 Ocular hypertension LLT
    12.1 10036719 Primary open angle glaucoma LLT
    12.1 10035015 Pigmentary glaucoma LLT
    12.1 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) ES (Completed) PT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:33:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA